Skip to contentD
DiaMedica Therapeutics Inc.
D
DMACDiaMedica Therapeutics Inc. Released May 6, 2026, after the close
10-Q filed May 6, 2026, 36 days after period end · 0001437749-26-015220
Q1 2026 · 10-Q
Revenue—
Net Income-$10.04M-$10.04MN/M vs Q1 2025N/M vs Q4 2025 EPS, diluted
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
DiaMedica Therapeutics Inc. · CIK 1401040 · Engraved from SEC EDGAR
—
Operating Income-$10,482,000N/M Operating Cash Flow-$9,082,000N/M Free Cash Flowderived-$9,090,000N/M ended Mar 31, 2026 · filed May 6, 2026 · 36 d after period end
0.3% from the close of May 6, 2026 to the close of May 7, 2026, the first after the release.
after the close$6.54$6.52 Apr 15May 6May 29